These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 19648740)

  • 1. Serum levels of 5-s-cysteinyldopa are correlated with skin colors in hemodialysis patients but not in peritoneal dialysis patients.
    Murakami K; Nakanishi Y; Wakamatsu K; Yamamoto K; Kohriyama N; Hasegawa M; Tomita M; Nabeshima K; Hiki Y; Asano S; Kawashima S; Ito Y; Fujita Y; Asada H; Nakai S; Sugiyama S; Ito S
    Blood Purif; 2009; 28(3):209-15. PubMed ID: 19648740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of pigmentation markers are elevated in patients undergoing hemodialysis.
    Murakami K; Wakamatsu K; Nakanishi Y; Takahashi H; Sugiyama S; Ito S
    Blood Purif; 2007; 25(5-6):483-9. PubMed ID: 18089933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative comparison of skin colors in patients with ESRD undergoing different dialysis modalities.
    Lai CF; Kao TW; Tsai TF; Chen HY; Huang KC; Wu MS; Wu KD
    Am J Kidney Dis; 2006 Aug; 48(2):292-300. PubMed ID: 16860196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of dialysis modality on skin hyperpigmentation in haemodialysis patients.
    Moon SJ; Kim DK; Chang JH; Kim CH; Kim HW; Park SY; Han SH; Lee JE; Yoo TH; Han DS; Kang SW
    Nephrol Dial Transplant; 2009 Sep; 24(9):2803-9. PubMed ID: 19342419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
    Lobo J; Santos F; Grosso D; Lima R; Barreira AL; Leite M; Mafra D; Abdalla DS
    Nephron Clin Pract; 2008; 108(4):c298-304. PubMed ID: 18434752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone, IGF-I and its binding proteins (IGFBP-1 and -3) in adult uraemic patients undergoing peritoneal dialysis and haemodialysis.
    Iglesias P; Díez JJ; Fernández-Reyes MJ; Méndez J; Bajo MA; Aguilera A; Selgas R
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):741-9. PubMed ID: 15163339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease.
    Díez JJ; Iglesias P; Fernández-Reyes MJ; Aguilera A; Bajo MA; Alvarez-Fidalgo P; Codoceo R; Selgas R
    Clin Endocrinol (Oxf); 2005 Feb; 62(2):242-9. PubMed ID: 15670203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
    Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
    J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum ghrelin concentrations in patients with chronic renal failure undergoing dialysis.
    Iglesias P; Díez JJ; Fernández-Reyes MJ; Codoceo R; Alvarez-Fidalgo P; Bajo MA; Aguilera A; Selgas R
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):68-73. PubMed ID: 16402931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma ghrelin levels in patients undergoing haemodialysis and peritoneal dialysis.
    Pérez-Fontán M; Cordido F; Rodríguez-Carmona A; Peteiro J; García-Naveiro R; García-Buela J
    Nephrol Dial Transplant; 2004 Aug; 19(8):2095-100. PubMed ID: 15187192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between body mass index and body fat in chronic kidney disease stages 3 to 5, hemodialysis, and peritoneal dialysis patients.
    Leinig C; Pecoits-Filho R; Nascimento MM; Gonçalves S; Riella MC; Martins C
    J Ren Nutr; 2008 Sep; 18(5):424-9. PubMed ID: 18721737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between some anthropometric measurements in adequately treated peritoneal dialysis and hemodialysis patients.
    Grzebalska AM; Majdan M; Bober E; Orłowska-Kowalik G; Ksiazek A
    Ann Univ Mariae Curie Sklodowska Med; 2004; 59(1):20-3. PubMed ID: 16145949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients.
    Arikan H; Koc M; Sari H; Tuglular S; Ozener C; Akoglu E
    Ren Fail; 2007; 29(6):713-9. PubMed ID: 17763167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis.
    Cano AE; Neil AK; Kang JY; Barnabas A; Eastwood JB; Nelson SR; Hartley I; Maxwell D
    Am J Gastroenterol; 2007 Sep; 102(9):1990-7. PubMed ID: 17511755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of dialysis on gastroesophageal reflux, dyspepsia, and proton pump inhibitor treatment in patients with chronic renal failure.
    Strid H; Fjell A; Simrén M; Björnsson ES
    Eur J Gastroenterol Hepatol; 2009 Feb; 21(2):137-42. PubMed ID: 19212202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-DR expression and apoptosis: a cross-sectional controlled study in hemodialysis and peritoneal dialysis patients.
    de Cal M; Cruz DN; Corradi V; Nalesso F; Polanco N; Lentini P; Brendolan A; Tetta C; Ronco C
    Blood Purif; 2008; 26(3):249-54. PubMed ID: 18376106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels.
    Borazan A; Ustün H; Ustundag Y; Aydemir S; Bayraktaroglu T; Sert M; Yilmaz A
    Mediators Inflamm; 2004 Jun; 13(3):201-4. PubMed ID: 15223612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of endocrine disrupting substance on estrogen receptor gene transcription in dialysis patients.
    Kanno Y; Okada H; Kobayashi T; Takenaka T; Suzuki H
    Ther Apher Dial; 2007 Aug; 11(4):262-5. PubMed ID: 17661831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease.
    Berger A; Edelsberg J; Inglese GW; Bhattacharyya SK; Oster G
    Am J Manag Care; 2009 Aug; 15(8):509-18. PubMed ID: 19670954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-free plasma DNA during peritoneal dialysis and hemodialysis and in patients with chronic kidney disease.
    Korabecna M; Opatrna S; Wirth J; Rulcova K; Eiselt J; Sefrna F; Horinek A
    Ann N Y Acad Sci; 2008 Aug; 1137():296-301. PubMed ID: 18837963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.